Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • SGK
    (6)
  • PROTAC Linker
    (4)
  • PROTACs
    (2)
  • ROCK
    (2)
  • Akt
    (1)
  • JNK
    (1)
  • PKA
    (1)
  • S6 Kinase
    (1)
  • Target Protein Ligand-Linker Conjugate
    (1)
  • Others
    (4)
TargetMol | Tags By ResearchField
  • Cancer
    (6)
Filter
Search Result
Results for "

sgk3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    10
    TargetMol | All_Pathways
  • PROTAC Products
    7
    TargetMol | PROTAC
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Antibody Products
    3
    TargetMol | Antibody_Products
PROTAC SGK3 degrader-1
SGK3-PROTAC1
T138472381320-35-8
PROTAC SGK3 degrader-1 (SGK3-PROTAC1) is a PROTAC coupler that targets SGK3 and binds ligand to VH032 VHL, inducing degradation of endogenous SGK3. It inhibits GDC0941-induced proliferation of cancer cells. [5017-88-83-4]
  • $479
Inquiry
Size
QTY
AT13148
T24821056901-62-2
AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II.
  • $30
In Stock
Size
QTY
PROTAC SGK3 degrader-2
T2125602381196-78-5
PROTACSGK3degrader-2 is the cis-diastereomer of PROTACSGK3degrader-1 (SGK3-PROTAC1), featuring a cis-hydroxy group in its VH032 section, which prevents binding to the VHL E3 ligase. This compound inhibits SGK3, SGK1, and S6K1 with IC50 values of 0.6 μM, 1.4 μM, and 1.7 μM, respectively, but does not degrade SGK3. It serves as a control compound for studying the specific degradation effects mediated by SGK3-PROTAC1.
  • Inquiry Price
Inquiry
Size
QTY
PT109
T2012732059104-90-2
PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.
  • $1,520
4-6 weeks
Size
QTY
OTs-C6-OBn
T18513126519-80-0
OTs-C6-OBn, an alkyl chain-based PROTAC linker, is utilized in the synthesis of PROTAC SGK3 degrader-1[1].
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ald-CH2-PEG3-CH2-Boc
T141582100306-54-3
Ald-CH2-PEG3-CH2-Boc, a PEG- and Alkyl/ether-based PROTAC linker, is utilized for the synthesis of SGK3 kinase PROTAC degrader[1].
  • Inquiry Price
Inquiry
Size
QTY
Boc-C1-PEG3-C4-OBn
T176462381196-81-0
Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PEG-based PROTAC linker used in the synthesis of various PROTACs, including PROTAC SGK3 degrader-1. PROTACs consist of two distinct ligands connected by a linker; one ligand binds to an E3 ubiquitin ligase, while the other specifically interacts with the target protein, enabling selective degradation of target proteins via the intracellular ubiquitin-proteasome system[1].
  • $30
Inquiry
Size
QTY
PEG3-C4-OBn
T185332381196-79-6
PEG3-C4-OBn, a polyethylene glycol (PEG)-based PROTAC linker, is utilized in crafting the PROTAC SGK3 degrader-1, a potent SKG3 degrader leveraging PROTAC technology [1][2].
    Inquiry
    308-R-C4-PEG3-C1-Boc
    T2121002376722-89-1
    308-R-C4-PEG3-C1-Boc is an SGK3 ligand-linker conjugate, utilized in the synthesis of PROTAC SGK3 degrader-2.
    • Inquiry Price
    Inquiry
    Size
    QTY
    SGK1 inhibitor
    T719471426214-51-8
    SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2. It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP. SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells and decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719. SGK1 inhibitor reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719.
    • $93
    35 days
    Size
    QTY